• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Tirzepatide Linked to “Impressive” BP Reduction in Adults with Obesity: Daily Dose

Tirzepatide Linked to “Impressive” BP Reduction in Adults with Obesity: Daily Dose / Image Credit: ©New Africa/AdobeStock
©New Africa/AdobeStock

Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.

Last week, we reported on findings of a substudy of the phase 3 SURMOUNT-1 clinical trial published in Hypertension.

The study

SURMOUNT-1, part of the tirzepatide clinical trial program, was a double-blind randomized, placebo-controlled trial to assess the effects of once-weekly subcutaneous tirzepatide dosed at 5 mg, 10 mg, or 15 mg on weight loss. The trial enrolled 2539 patients with a BMI of 30 kg/m2 or greater or 27 kg/m2 plus at least 1 weight-related complication, excluding diabetes, and assigned them randomly in a 1:1:1:1 ratio to the study treatments and placebo. Overall, SURMOUNT-1 participants who received tirzepatide lost between 16% and 22.5% of their baseline bodyweight.

The substudy was designed to assess specifically on 24-hour ambulatory blood pressure (ABP) and enrolled 600 of the original study participants. All substudy participants had BP levels less than 140/90 mm Hg, and if taking medication for hypertension were required to have been on stable doses for at least 3 months when the substudy began. Among these participants, 145 were assigned to tirzepatide 5 mg, 152 to tirzepatide 10 mg, 148 to tirzepatide 15 mg, and 155 assigned to placebo.

The findings

Compared with participants receiving placebo, tirzepatide-treated participants (mean BMI 37.4 kg/m2) achieved mean 24-hour ABPM reductions of 7.4 mm Hg (tirzepatide 5 mg), 10.6 mm Hg (10 mg), and 8.0 mm Hg (15 mg) over the 36-week study period. Moreover, the investigators emphasized that the results were consistent for overnight as well as daytime BP and consistent across study subgroups.

Authors' comment

"These data provide further evidence for the potential benefits of tirzepatide on cardiometabolic health and cardiovascular outcomes."

Click here for more details.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
© 2024 MJH Life Sciences

All rights reserved.